Introduction ▼
Hyperthyroidism is a commonly found endocrine pathology, with a prevalence of 2 % in women and 0.2 % in men, and an incidence of 20 / 1 000 000 / year in general population, with a male / female ratio of 1 / 5 -7 ( Abraham et al., 2005 ; Dasgupta and Savage, 2005 ) . Causes of hyperthyroidism are Graves ' disease, toxic multinodular goitre, solitary hyperfunctioning nodules, autoimmune postpartum, subacute thyroiditis, tumours that secrete thyrotropin, drug-induced thyroid dysfunction. However, the most prominent cause of hyperthyroidism in iodine-suffi cient areas is Graves ' disease (80 % of all hyperthyroidism cases) ( Streetman and Khanderia, 2003 ) , while autonomous hyperfunctioning adenomas are more common in regions of iodine defi ciency ( Bauch, 1998 ; Iagaru and McDougall, 2007 ) . Graves ' disease is characterised by an evident familial predisposition, with a peak of incidence between 20 -40 yr, and by association with autoimmune pathologies such as thyroiditis, pernicious anemia and diabetes mellitus type 1 ( Streetman and Khanderia, 2003 ) . This illness has unknown autoimmune aetiology and is characterised by the presence of circulating antibodies that bind to the TSH receptor and activate it, stimulating the growth and the activity of Pearce and Braderman, 2004 ; Cooper, 2005 ) . These drugs bind serum proteins diff erently: the MMI is more liposoluble and is free in the serum, while the 80 -90 % of PTU is bound to albumin. Both drugs cross the placenta and are found in maternal milk at diff erent concentrations (MMI / PTU = 4 -7) ( Streetman and Khanderia, 2003 ) .
Pharmacodynamic characteristics
MMI and PTU are actively concentrated by the thyroid against a concentration gradient. Their primary eff ect is to inhibit the intra-and extra-thyroid hormonal synthesis. Intra-thyroid eff ects ▶ Inhibition of iodide organifi cation ▶ Inhibition of iodide incorporation in the thyrosine residues of thyroglobulin ▶ Inhibition of pairing of iodothyrosines These eff ects are determined by inhibition of thyroid peroxidase action. This enzyme is a glycoprotein with a heme group fi xed to the cellular membrane of the thyroid follicle on the luminal side. After the catching of iodide through NIS (NA + / I-symporter), that is organifi cated into iodine through an intermediated compound (TPO-Iox). Subsequently, this compound reacts with thyrosine residues of thyroglobulin to form monoiodothyrosine (MIT) and diiodothyrosine (DIT). From the pairing of one MIT and one DIT molecule derives triiodothyronine (T3), while from two DIT derive tetraiodthyronine or thyroxine (T4). Thionamides, with chemical structure similar to thyrosine residues, compete with them to bound to TPO-Iox, blocking the action of TPO and so the subsequent steps of hormone synthesis. ▶ Immunosoppressive eff ects. Several studies showed that antithyroid drugs can directly promote the apoptosis of intrathyroidal lymphocites ( Mitsiades et al., 2000 ) , and reduce the expression of HLA class-II molecules ( Zantut-Wittmann et al., 2001 ), the number of activate T-cells and natural-killer cells ( Wang et al., 1988 ) . Moreover, it can be hypothesized that the thyroid-function normalization itself could be sufficient to reduce the immunological response ( Volp é , 2001 ). Extra-thyroid eff ects ▶ Inhibition of the conversion of T4 to T3, due to the blocking of deiodinase-type-1 action ( Koenig, 2005 ) . It has been reported that PTU, but not MMI, reacts with the selenenyl iodide intermediate of deiodinase-type-1 to form a selenenyl sulfi de and thereupon blocking the conversion of T4 to T3 during the monodeiodination reaction ( Roy and Mugesh, 2006 ) . ▶ Inhibition of thyroid-hormone transcriptional eff ects, due to the impaired bound to T3 nuclear receptors and to the recruitment of co-suppressor, and / or to the dissociation of co-activators ( Takagi et al., 1990 ) .
Clinical use of thionamides
Antithyroid drugs can be used both in the primary treatment of hyperthyroidism (long-term therapy: 1 -2 yr) and as a preparation for radiometabolic or surgical treatment (short-term therapy: weeks or months). The elective indication for pharmacological therapy are: mild or moderate hyperthyroidism, slight increase of gland volume, pediatric or adolescent age, pregnancy or breast-feeding, and ophtalmopathy that could be worsened by radiometabolic therapy ( Table 1 ) . On the contrary, the thyonamides are not generally considered drugs of fi rst choice in hyperthyroid subjects with elevated probability of recurrence, such as patients with multinodular toxic goitre, autonomous nodule, voluminous goitre, persistently elevated levels of anti TSH-receptor antibodies ( Table 2 ) ( Cooper, 2005 ) .
Methimazole vs. Propylthiouracil
Initial doses: eff ectiveness and remission In the therapy of Graves ' disease, the choice of MMI or PTU is controversial ( The results showed that in the case of mild or moderate hyperthyroidism (FT4 < 7 ng / dl), the effi cacy in lowering the serum levels of thyroid hormones was the same for all 3 groups. On the contrary, in the case of severe hyperthyroidism (FT4 ≥ 7 ng / dl), the group treated with a high dose of MMI reached a more rapid normalisation of FT4 levels both with respect to the group treated with a lower dose of MMI and to the group treated with PTU ( Nakamura et al, 2007 ) . However, diff erent randomised prospective studies have shown that the dosage does not signifi cantly infl uence the percentage of remissions ( Reinwein et al., 1993 ) . Therefore, in case of mild or moderate hyperthyroidism it is suffi cient to use methimazole in low doses, while in the case of severe hyperthyroidism, in order to reach euthyroidism in a Table 1 Thionamide fi rst-choice indications.
-mild / moderate hyperthyroidism -mild thyroid volume increase -orbitopathy -pregnancy and breast-feeding -young age Table 2 Conditions increasing relapse rates.
-goiter -multinodular toxic goiter -autonomous single nodule -persistence of high rates of TRAb shorter time, a higher dose of MMI is recommended. Currently, PTU is not recognised as a drug of fi rst choice in the treatment of hyperthyroidism, because of its lower adherence rates (due to the necessity of taking the drug several times a day) and major toxicity, leading in particular to severe liver failure ( Cooper and Rivkees, 2009 ).
Maintenance doses during treatment
Maintenance doses correspond to 5 -10 mg every day for MMI and 50 -100 mg for PTU. The duration of the therapy should be between 12 and 18 months. A comparison between 4 randomised prospective studies has showed that periods of treatment inferior to 12 months lead to a higher possibility of recurrence, while periods superior to 18 months do not lead to higher percentages of remissions ( • ▶ Fig. 1 ) ( Cooper, 2003 ) . In the management of thionamide therapy it is important to know that these drugs do not block the release of pre-formed thyroid hormones and that, therefore, the state of euthyroidism is usually reached within 4 -12 weeks. Furthermore, it has to be considered that diff erent factors infl uence the rapid control of hyperthyroidism, such as the initial levels of thyroid hormones, iodine pool, and intrathyroid hormonal deposits, the size of the gland, and the stage of the disease. A recent meta-analysis has included 12 trials comparing the administration of levothyroxine in addition to a thionamide therapy (the so-called blockand-replace regimen) with the thionamide therapy alone (titration regimen) and has demonstrated that their eff ectiveness is comparable. However, the block-and-replace regimen requires higher doses of thyonamides and is associated with signifi cantly higher rates of reported side eff ects: it is therefore not advised ( Abraham et al., 2005 ) .
Side eff ects
Thionamides can be associated with a variety of side eff ects with diff erent severity levels, grouped as minor and major ( Streetman and Khanderia, 2003 ; Pearce and Braderman, 2004 
Thionamides and radiometabolic therapy
Radiometabolic therapy can be associated with both long-and short-term side eff ects. Among the fi rst is radio-induced thyrotoxicosis, a condition of acute release of thyroid hormones in circulation with a potential exacerbation of hyperthyroidism ). The mortality associated with the latter condition is 25 % , principally due to cardio-and cerebrovascular events ( Nayak and Burman, 2006 ) . The use of thionamides before radiometabolic therapy could reduce the degree of biochemical and clinical condition, even if such use still remains debated ( Walter et al., 2007 ) . Some studies show that although an increase of FT3 and FT4 can occur in patients pretreated with antithyroid drugs, the levels reached are lower than those found in non-pretreated patients. Such a diff erence could be linked to the fact that patients pretreated with thionamides start the radiometabolic therapy with lower baseline serum-levels of hormones than non-pretreated patients ( Burch et al., 2001 ). Two mechanisms seem to be involved in this thionamide action: the depletion of thyroid hormonal deposits before radiometabolic therapy, and the slowdown in the production of TSH-receptor antibody after therapy. In addition, the use of MMI would bring a more rapid control of thyrotoxicosis than the use of PTU ( Cooper, 2003 ) . Alongside these studies, others, among which a recent systematic review with a meta-analysis of 14 randomised control trials ( Walter et al., 2007 ) , have shown that the eff ect of thionamides on the attenuation of biochemical and clinical thyrotoxicosis in the weeks following radiometabolic therapy has not been systematically monitored. For this reason, it remains uncertain whether thionamides should be used in such conditions. Another controversial question is the role of thionamides in the effi cacy of radiometabolic therapy and the diff erence in the percentages of radio-iodine therapy failures between PTU and MMI. Pretreatment with thionamides reduces the uptake of radioiodine and in addition inhibits thyroperoxidase. A recent metaanalysis ( Walter et al., 2007 ) has demonstrated that both drugs increase the rate of radiotherapy failure, without a signifi cant diff erence between PTU and MMI. Nonetheless, non-randomised studies included in the meta-analysis suggested more defi nite and prolonged negative eff ects with PTU. The study suggests that the effi cacy reduction can be compensated for by higher doses of radioiodine, while the use of MMI would be preferable to that of PTU and must be interrupted three days before the beginning of radioiodine therapy. The indications for treatment with thionamides before radiotherapy particularly concern older patients and patients with serious cardiovascular diseases.
The main long-term side eff ect of radiometabolic therapy is hypothyroidism (80 -90 % ), which can occur even some years after treatment. Such a condition is due to necrosis, reduced replication of the residual follicular cells, atrophy, fi brosis and chronic infl ammatory conditions that can lead to permanent thyroid damage ( Bonnema et al., 2003 ) . In the previously cited meta-analysis it was shown that the administration of thionamides during or after radioiodine treatment reduces the risk of hypothyroidism, although this fact remains still uncertain ( Cooper, 2003 ; Walter et al., 2007 ; Chiovato et al., 1998 ) . Potassium perchlorate can be used in the treatment of thyrotoxicosis due to excess of exogenous iodine, particularly in type-1 amiodarone-induced thyrotoxicosis. The drug competitively inhibits the uptake of iodide by thyroid cells and accelerates its release. The initial dose is 250 mg every 6 h by oral administration. It must be underlined that this substance can produce various side eff ects, among which the most serious is bone-marrow depression, which can lead to medullary aplasia.
Beta blockers
Beta-adrenergic blockers play an important role in the management of patients with Graves ' disease, particularly as an adjuvant therapy associated with antithyroid drugs, if there are no contraindications. Many typical symptoms of hyperthyroidism, such as palpitations, anxiety, tremors and heat intolerance mimic the eff ects of an excessive beta-adrenergic activity which explains the effi cacy of beta-blockers. Propranolol is one of the most used, because, in addition to reducing the sympatheticomimetic eff ects, it also inhibits the peripheral conversion of T4 into T3. The initial dose of propranolol is 12 -20 mg 3 times per day for oral administration and is gradually reduced as thyrotoxicosis improves. Atenolol (25 -50 mg per day) can be used in alternative to propranolol, particularly in patients with bronchopathy, as it is the most cardioselective beta-blocker ( Streetman 
Inorganic iodide and Iodinated contrast media
Iodine is a necessary element for the correct function of the thyroid gland. A sudden increase of circulating iodine causes an antithyroidal eff ect, the Wolff -Chaikoff eff ect. An excess of iodide blocks the action of thyroperoxidase with a reduction of oxidation and organifi cation of iodide and consequently causes a rapid block of thyroid hormone release. Even if patients aff ected by Graves ' disease are subject to this inhibitory action more than healthy subjects, this eff ect has a very short action. Actually, potassium iodide, administered orally as Lugol solution (61 mg of iodide per drop) or as a saturated solution (SSKI 40 mg of iodide per drop) is not considered the therapy of fi rst choice in the treatment of hyperthyroidism, since the inhibitory eff ect is transitory and the elimination period is approximately 10 -14 days. Nowadays, Lugol solution can be used as a pretreatment to a total thyroidectomy intervention since it reduces the glandular vascularisation; in the management of severe forms of thyrotoxicosis as it establishes a rapid block of thyroid hormone release; and as an adjuvant therapy in radiometabolic treatment.
In the latter case, potassium iodide should be administered one week after the dose of radioiodine, to avoid interfering eff ects. Iodinated contrast media, such as sodium ipoiodate and iopanoic acid, reduce the peripheral conversion of T4 into T3 by approximately 70 % , and can be used in the thyrotoxicosis crisis, in pre-operatory preparation and as an alternative therapy for patients allergic to antithyroid drugs. The side eff ects are minimal and include cutaneous rash, nausea, vomiting, diarrhea, dysuria and, only in rare cases, acute renal failure and thrombocytopenia ( Pearce and Braderman, 2004 ) .
Lithium Carbonate
The antithyroidal eff ect of lithium has been noted since 1960, even though its exact mechanism of action is still unclear.
However, it seems that lithium, similarly to iodide, blocks the release of thyroid hormones for a transitory period. For this reason and for possible side eff ects linked to its administration, the use of lithium carbonate in the treatment of hyperthyroidism in Graves ' disease is limited. Sometimes it can be used as an adjuvant to radiometabolic therapy to prevent an increase of serum thyroid-hormone concentration ( Streetman and Khanderia, 2003 ; Pearce and Braderman, 2004 ) .
Glucocorticoids
Glucocorticoids are used in thyrotoxicosis in which iodine produces a destroying eff ect on the thyroid tissue, such as in the initial phases of subacute thyroiditis or in type-2 amiodaroneinduced thyrotoxicosis. The eff ect of the glucocorticoids is twofold, anti-infl ammatory action and a reduction in the peripheral conversion of T4 into T3. One can use methylprednisolone at a dose of 20 -40 mg / die or dexamethasone at a dose of 3 -6 mg / die, achieving euthyroidism generally within 1 -3 weeks. Steroids are gradually reduced and suspended only 2 -3 months after the start of the treatment in order to avoid possible relapses.
Biologic drugs ▼
Rituximab ( ( Dass et al., 2007 ) . Moreover, the FDA has recently warned against an increased risk of progressive multifocal leucoencephalopathy, a serious and usually fatal demyelinating disorder caused by JC polyoma virus ( Carson et al., 2009 ).
In conclusion, RTX administration for Graves ' disease is off -label and experimental: because of the limited experience, the high cost, the peculiar side-eff ect profi le, and the availability of alternative well-studied therapies, RTX currently should not be considered as an option in uncomplicated Graves ' disease.
Summary ▼ MMI and PTU inhibit the synthesis of thyroid hormone at various levels and are used as the primary treatment for hyperthyroidism or as a preparation before radioiodine therapy or thyroidectomy. MMI is the drug of choice because of its widespread availability, longer half-life and less frequent serious side eff ects. PTU should be reserved to patients who are intolerant of MMI, or to women in their fi rst trimester of pregnancy. The initial dose of MMI is usually 10 -30 mg per day in one oral administration, while that of PTU is 100 -300 mg per day every 6 h. Maintenance dose is 5 -10 mg per day for MMI and 50 -100 mg for PTU. The titration regimen and the block-and-replace regimen have a comparable eff ectiveness: however, the latter is not advised because of higher doses requested and higher rates of reported side eff ects. During thionamide administration, it would be necessary to monitor both the eff ectiveness of treatment and the possible occurrence of severe side eff ects (mainly agranulocytosis and liver toxicity). Patients should undergo evaluation of FT3, FT4, TSH, complete blood-cell count, and liver-function test every 4 -6 weeks during the initial stages of treatment and every 2 -3 months thereafter. Drugs of second choice are potassium perchlorate, beta blockers, iodine, lithium carbonate and glucocorticoids. Rituximab, a B-cell depleting monoclonal antibody, was recently proposed as a biological therapy for cases of Graves ' disease unresponsive to traditional drugs. However, RTX currently should not be considered as an option in uncomplicated Graves ' disease, due to the limited experience, the high cost, and the peculiar side-eff ect profi le.
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